No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T11:36:18.884Z. Latest historical point 2026-10-05.
The latest delayed quote for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock was $10.90 as of Oct 5, 2026, 1:49 PM EDT, up 0.09% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +6.0%
Drugs Made In America Acquisition Corp. does not have significant operations.
Shell Companies · New York, NY
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DMAA | $264.62M | $10.90 | +0.09% | +6.01% | N/A | N/A | N/A |
| 2TBCVU | $266.32M | $9.92 | -0.10% | N/A | N/A | N/A | vs DMAA |
| 3CEPV | $262.30M | $10.27 | -0.19% | N/A | N/A | N/A | vs DMAA |
| 4AMAC | $261.73M | $9.80 | +0.00% | N/A | N/A | N/A | vs DMAA |
| 5ARTC | $261.51M | $10.01 | -0.10% | N/A | N/A | N/A | vs DMAA |
| 6FACT | $260.97M | $10.73 | +0.09% | +3.96% | N/A | N/A | vs DMAA |
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$10.90
High
N/A
